Is WAT a good stock to buy? We came across a bullish thesis on Waters Corporation on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on WAT. Waters Corporation’s share was trading at $301.88 as of May 4th. WAT’s trailing and forward P/E were 28.54 and 21.37 respectively according to Yahoo Finance.
Pixabay/Public Domain
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. WAT recently experienced a sharp selloff following its Q4 2025 results and the closing of its transformative merger with BD’s Biosciences and Diagnostic Solutions division, creating a compelling entry point into a high-quality analytical instruments business.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Despite near-term concerns around integration, the core Waters business remains fundamentally strong, generating $762 million in operating cash flow with industry-leading margins and a resilient model built on liquid chromatography, mass spectrometry, and thermal analysis tools. The company benefits from a highly recurring revenue base, with 57% of sales derived from consumables and service contracts, and a sticky customer base led by pharma and biopharma clients, which account for 58% of revenue.
Financially, Waters has demonstrated consistent profitability, with FY2025 non-GAAP EPS growing 11% to $13.13 and free cash flow conversion exceeding 100% of net income, highlighting exceptional cash generation. At current levels, the stock trades at approximately 24x earnings, a meaningful discount to its historical 38–42x range and below sector averages, despite maintaining ~59% gross margins and strong liquidity metrics, including a 1.53x current ratio.
The BD merger more than doubles revenue and introduces significant long-term synergies, positioning the combined entity for 10%+ EPS growth and substantial scale benefits. While integration and elevated leverage present short-term risks, robust cash flows provide a clear path to deleveraging. With secular tailwinds from pharma innovation, instrument replacement cycles, and expanding global demand, Waters offers an attractive risk-reward profile, where successful execution could drive meaningful multiple expansion and sustained shareholder returns.
Previously, we covered a bullish thesis on Thermo Fisher Scientific Inc. (TMO) by Kontra in October 2024, which highlighted the company’s positioning as a quality compounder driven by its diversified life sciences portfolio and strong competitive advantages. TMO’s stock price has depreciated by approximately 23.11% since our coverage. The Wealth Dynasty Report shares a similar view but emphasizes on Waters Corporation’s discounted valuation and integration-driven upside.
